- Home
- MVST vs GHRS Comparison
MVST vs GHRS Comparison
Compare MVST & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MVST | GHRS |
|---|---|---|
| Founded | 2006 | 2018 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 987.8M | 947.2M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | MVST | GHRS |
|---|---|---|
| Price | $1.53 | $23.94 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | $6.00 | ★ $41.38 |
| AVG Volume (30 Days) | ★ 5.0M | 190.3K |
| Earning Date | 05-11-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $24.55 | N/A |
| Revenue Next Year | $17.08 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.17 | $10.96 |
| 52 Week High | $7.12 | $24.66 |
Technical Indicators
Market Signals| Indicator | MVST | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 46.81 | 66.60 |
| Support Level | $1.51 | $12.65 |
| Resistance Level | $2.16 | $24.66 |
| Average True Range (ATR) | 0.15 | 1.55 |
| MACD | 0.01 | -0.04 |
| Stochastic Oscillator | 35.15 | 92.71 |
Price Performance
Historical ComparisonAbout MVST Microvast Holdings Inc.
Microvast Holdings Inc is a technology innovator that designs, develops, and manufactures lithium-ion battery solutions. It is renowned for its cutting-edge cell technology and its vertical integration capabilities which extends from core battery chemistry to battery packs.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.